# US 2016/0257958 A1 · Hepcidin Binding Nucleic Acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257958 A1
- Document ID: US20160257958A1
- Status: Published application
- Kind: A1
- Application number: 14/493,435
- Filed: 2014-09-23
- Published: 2016-09-08
- Earliest claimed: 2009-04-30
- Assignees: NOXXON Pharma AG
- Applicants: Noxxon Pharma AG
- Inventors: Simone Sell; Frank Morich; Christian Maasch; Sven Klussmann; Nicole Dinse; Klaus Buchner; Frank Schwobel
- Web page: https://patentgrep.com/patent/US20160257958A1

## CPC

- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- C12N 2310/16: Aptamers
- C12N 2310/351: Conjugate
- C12N 2320/30: Special therapeutic applications
- G01N 2333/575: Hormones
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention is related to a nucleic acid capable of binding to hepcidin.

## Claims

### Claim at position 1

1-99. (canceled)

### Claim 100

An L-nucleic acid that binds hepcidin, wherein the L-nucleic acid comprises in 5→43′ direction a first terminal stretch of nucleotides, a central stretch of nucleotides and a second terminal stretch of nucleotides, wherein the central stretch of nucleotides comprises
5′ RKAUGGGAKUAAGUAAAUGAGGRGUWGGAGGAAR 3′ [SEQ II) NO: 182] or
5′ RKAUGGGAKAAGUAAAUGAGGRGUWGGAGGAAR 3′ [SEQ ID NO:183], and
the first terminal stretch of nucleotides comprises five to eight nucleotides, and the second terminal stretch of nucleotides comprises five to eight nucleotides.

### Claim 101 (depends on 100)

The L-nucleic acid according to claim 100, wherein the nucleic acid is an antagonist of hepcidin.

### Claim 102 (depends on 100)

The L-nucleic acid according to claim 100, wherein the nucleic acid is an inhibitor of the hepcidin-ferroportin system.

### Claim 103 (depends on 100)

The L-nucleic acid according to claim 100, wherein the central stretch of nucleotides is essential for binding to hepcidin.

### Claim 104 (depends on 100)

The L-nucleic acid according to claim 100, wherein the central stretch of nucleotides comprises 5′ RKAUGGGAKUAAGUAAAUGAGGRGUUGGAGGAAR 3′ [SEQ ID NO:213].

### Claim 105 (depends on 100)

The L-nucleic acid according to claim 100, wherein the first terminal stretch of nucleotides and the second terminal stretch of nucleotides optionally hybridize with each other to form a double-stranded structure.

### Claim 106 (depends on 100)

The L-nucleic acid molecule according to claim 100, wherein the first terminal stretch of nucleotides comprises 5 X1X2X3SBSBC3′ and the second terminal stretch of nucleotides comprises 5′ GVBVBX4X5X6 3′, wherein
a) X1 is A, X2 is G, X3 is B, X4 is S, X5 is C, and X6; is U or
b) X1 is absent, X2 is G, X3 is B, X4 is S, X5 is C, and X6 is U or
c) X1 is A, X2 is G, X3 is B, X4 is S, X5 is C, and X6 is absent.

### Claim 107 (depends on 100)

The L-nucleic acid molecule according to claim 100, wherein the first terminal stretch of nucleotides comprises 5′ X1X2X3SBSBC3′ and the second terminal stretch of nucleotides comprises 5′ GVBVYX4X5X6 3′, wherein
a) X1 is absent, X2 is G, X3 is B, X4 is S, X5 is C, and X6 is absent or
b) X1 is absent, X2 is absent, X3 is B, X4 is S, X5 is C, and X6 is absent or
c) X1 is absent, X2 is G, X3 is B, X4 is S, X5 is absent, and X6 is absent.

### Claim 108 (depends on 100)

The L-nucleic acid molecule according to claim 100, wherein the first terminal stretch of nucleotides comprises 5′ X1X2X3SBSBC3′ and the second terminal stretch of nucleotides comprises 5′ GVBVYX4X5X6 3′, wherein X1 is absent, X2 is absent, X3 is B or absent, X4 is S or absent, X5 is absent, and X6 is absent.

### Claim 109 (depends on 100)

The L-nucleic acid according to claim 100, wherein the nucleic acid comprises a nucleic acid sequence according to any one of SEQ ID NOs:115 to 119, SEQ ID NO:121, SEQ. ID NO:142, SEQ ID NO:144, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:175 or SEQ ID NO:176.

### Claim 110 (depends on 100)

The L-nucleic acid according to claim 100, wherein hepcidin is selected from the group consisting of human hepcidin-25, human hepcidin-22, human hepcidin-20, monkey hepcidin-25, monkey hepcidin-22 and monkey hepcidin-20.

### Claim 111 (depends on 100)

The L-nucleic acid according to claim 100, wherein the L-nucleic acid binds human hepcidin-25.

### Claim 112 (depends on 100)

The L-nucleic acid according to claim 100, comprising a modification group.

### Claim 113 (depends on 112)

The nucleic acid according to claim 112, wherein the modification group is selected from the group consisting of linear polyethylene glycol (PEG), branched PEG, hydroxyethyl starch (HES), a peptide, a protein, a polysaccharide, a sterol, polyoxypropylene, polyoxyamidate and poly (2-hydroxyethyl)-L-glutamine.

### Claim 114 (depends on 112)

The L-nucleic acid according to claim 112, wherein the modification group comprises a straight or branched PEG.

### Claim 115 (depends on 114)

The L-nucleic acid according to claim 114, wherein the PEG is from about 20,000 to about 120,000 Da.

### Claim 116 (depends on 112)

The L-nucleic acid according to claim 112, wherein the modification group is a HES comprising a molecular weight of from about 10,000 to about 200,000 Da.

### Claim 117 (depends on 112)

The L-nucleic acid according to claim 112, wherein the modification group is coupled to the nucleic acid via a linker.

### Claim 118 (depends on 112)

The nucleic acid according, to claim 112, wherein the modification group is coupled to the 5′-terminal nucleotide and/or the 3′-terminal nucleotide of the nucleic acid.

### Claim 119 (depends on 100)

A pharmaceutical composition comprising the L-nucleic acid of claim 100 and optionally a further constituent selected from the group consisting of pharmaceutically acceptable excipients, pharmaceutically acceptable carriers and pharmaceutically active agents.

### Claim 120 (depends on 100)

A method of treating a disease or condition associated with hepcidin in a subject suspected of having said disease or condition, wherein the method comprises exposing the subject to the L-nucleic acid of claim 100.

### Claim 121 (depends on 120)

The method according to claim 120, wherein the disease or condition is selected from the group consisting of anemia, hypoferremia, pica, a condition with elevated hepcidin level, a condition with elevated iron level and a condition with iron overload.

### Claim 122 (depends on 121)

The method according to claim 121, wherein the anemia is selected from the group consisting of sideroblastic anemia, hypochromic microcytic anemia, anemia caused by chronic disease and/or disorder, anemia caused by inflammation, anemia caused by genetic disorders, anemia caused by acute infections, anemia caused by mutation in genes of iron and in homeostasis and anemia caused by cancer treatment.

### Claim 123 (depends on 100)

A complex comprising the L-nucleic acid according to claim 100 and hepcidin.

### Claim 124 (depends on 100)

A method for detecting hepcidin comprising exposing a sample suspected of comprising hepcidin with the L-nucleic acid according to claim 100 and determining presence of complexes of said L-nucleic acid and hepcidin, wherein presence of complexes correlates with presence of hepcidin in said sample.

### Claim 125 (depends on 100)

A method for identifying an antagonist or an agonist of hepcidin comprising:
providing a candidate antagonist and/or a candidate agonist of hepcidin,
providing the L-nucleic acid according to claim 100,
providing a test system which provides a signal in the presence of an antagonist and/or an agonist of hepcidin, and
determining whether the candidate antagonist is an antagonist of hepcidin and/or whether the candidate agonist is an agonist of hepcidin.

### Claim 126 (depends on 100)

A method for the detection of the L-nucleic acid according to claim 100 in a sample, wherein the method comprises the steps of:
a) providing a sample containing the L-nucleic acid according to claim 100;
b) providing a capture probe, wherein the capture probe is at least partially complementary to a first part of the L-nucleic acid according to any one of claim 100, and a detection probe, wherein the detection probe is at least partially complementary to a second part of the L-nucleic acid according to claim 100, or, alternatively, the capture probe is at least partially complementary to a second part of the L-nucleic acid according to claim 100 and the detection probe is at least partially complementary to the first part of the L-nucleic acid according to claim 100;
c) allowing the capture probe and the detection probe to react either simultaneously or in any order with the L-nucleic acid according to claim 100 or part thereof to form a complex;
d) optionally detecting Whether or not the capture probe is hybridized to the L-nucleic acid according to claim 100 provided in step a); and
e) detecting the complex formed in step c) consisting of the L-nucleic acid according to claim 100 the capture probe and the detection probe.
